Thousands of men could live longer with prostate cancer after taking a new drug combination. New research shows that the drug abiraterone significantly improves survival for patients with prostate cancer. The National Institute for Health and Care Excellence previously stated that Abiraterone is not a cost-effective treatment option for patients
“Based on these results, all men with high-risk non-metastatic prostate cancer should be considered for two years of abiraterone,” stated study co-author Professor Gerhardt Attard.
The costly pills each day cost £35,500 per year in privacy, however it is unknown how much NHS contributes. Nevertheless, abiraterone, given for only 2 years, greatly reduced death risks. This was identified in the new UK-led trial of a separate group of individuals whose prostate cancer had not been propagated. Specialists believe that after the findings the medication might be made accessible ‘soon’ to the NHS.Abiraterone stops cancer cells from producing or extracting male sex hormones, thereby reducing the likelihood that cells would proliferate and expand into bigger tumors.
“The results were spectacular – that is really the only word for it. “We are in active discussions with NHS England about how these findings can be implemented,” added author Nick James.
Prostate cancer is much more common in men than most people realize. In America, there were 191,000 new cases of prostate cancer last year. That’s more than triple what they were 30 years ago. American men live an average of eight years after being diagnosed with prostate cancer. But prostate cancer is not a silent killer. Over three million American men have been diagnosed with it: one of them is very likely to die within five years, and two of them within ten. The chances of dying from prostate cancer in any given year are something like one in six for a man who has not had the disease and between one in three and one in four for those who do.